Agronomics Limited Announces the Sale of InSilico Medicine Inc Shares (9149C)

TIDMANIC

RNS Number : 9149C

Agronomics Limited

24 June 2021

24 June 2021

Agronomics Limited

("Agronomics" or the "Company")

Announces the Sale of InSilico Medicine Inc Shares

Agronomics, the leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat, is pleased to announce the disposal of its total holding of 23,147 shares in Insilico Medicine Inc ("InSilico Medicine") for US $669,775 (GBP475,540), representing an IRR of 54%. Insilico Medicine was a legacy portfolio holding, acquired for GBP92,755 between June 2017 and July 2018. The proceeds will provide Agronomics with further funding for new and existing opportunities within the field of cellular agriculture.

The remaining legacy positions in the portfolio continue to be monitored and will be sold down as opportunities arise.

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 16 companies at the Seed to Series B stage in this rapidly advancing sector. It seeks to secure a 5-10% initial ownership in technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/portfolio/ .

About the Cultivated Meat Sector

Funding in the cultivated meat sector is growing rapidly with approximately US$ 170 million invested worldwide between 2016-2019 and over US$ 270 million raised in 2020 alone. Additional financings are anticipated as the capital requirements of these companies grows to build out and scale up manufacturing facilities. Currently it is estimated that there are 80 companies globally within the sector. AT Kearney, a global consultancy, has predicted that Cultivated Meat's market share of meat consumption will be 35% by 2040.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.

For further information please contact:

 
       Agronomics               Beaumont                 Cenkos            Peterhouse Capital         TB Cardew 
         Limited             Cornish Limited         Securities Plc              Limited 
      The Company                Nomad                Joint Broker            Joint Broker         Public Relations 
                        ----------------------  ----------------------  ----------------------  ---------------------- 
      Richard Reed           Roland Cornish          Giles Balleny           Lucy Williams            Ed Orlebar 
       Denham Eke             James Biddle             Nick Searle         Charles Goodfellow        Joe McGregor 
                        ----------------------  ----------------------  ----------------------  ---------------------- 
                                                                                                 [phone] 
                                                                                                 [phone] 
  [phone]                                                                           [e-mail] 
   [e-mail]     [phone]    [phone]    [phone]            m 
                        ----------------------  ----------------------  ----------------------  ---------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DISPPUCWQUPGGMW

(END) Dow Jones Newswires

June 24, 2021 02:00 ET (06:00 GMT)